More importantly, a Phase 1 study of BCMA and CD19-directed compound CAR-T therapy demonstrated the ability to simultaneously reset the humoral and B-cell immune systems and deplete disease-causing autoantibodies derived from B cells and long-lived plasma cells in patients with SLE/LN (108). The gene discussed is CD19; the disease is systemic lupus erythematosus.